Piramal Pharma Limited — Updates, 28-04-2026: Press Release

Piramal Pharma reported a FY26 net loss of ₹326 Cr, largely due to a ₹196 Cr intangible asset impairment. Revenue decreased 3%, EBITDA 28%. Q4 showed recovery with improving CDMO order inflows, CHG's Kenalog® acquisition (US$35Mn upfront), and PCH Power Brands growing 24%. Management anticipates FY27 growth.